```html

Chronic Hepatitis B: A Comprehensive Medical Guide

Overview

Chronic hepatitis B (CHB) is a long‑term infection of the liver caused by the hepatitis B virus (HBV). Unlike an acute infection that resolves within six months, CHB persists for more than six months and can lead to progressive liver damage.

HBV is a DNA virus transmitted through blood, sexual fluids, or from mother to child. An estimated 257 million people worldwide live with chronic hepatitis B, making it the most common chronic viral liver disease globally.<sup>[1] WHO, 2022</sup> In the United States, about 850,000 individuals are chronically infected.<sup>[2] CDC, 2023</sup>

CHB can affect anyone, but certain groups are at higher risk:

• Infants born to HBV‑positive mothers (especially in endemic regions)
• People who inject drugs or have multiple sexual partners
• Individuals receiving hemodialysis or transfusions before 1992 (when blood screening became universal in many countries)
• People from East Asia, Sub‑Saharan Africa, and the Pacific Islands where HBV prevalence exceeds 5%.

Symptoms

Many people with chronic hepatitis B are asymptomatic for years. When symptoms do appear, they often reflect liver inflammation or damage.

Common signs

• Fatigue – Persistent tiredness not explained by other causes.
• Jaundice – Yellowing of the skin and eyes due to elevated bilirubin.
• Right‑upper‑quadrant abdominal pain – Discomfort near the liver.
• Dark urine and pale stools – Result from impaired bilirubin excretion.
• Loss of appetite and nausea.
• Unexplained weight loss.

Less common but important signs

• Joint pain or arthralgia (often immune‑mediated).
• Skin rash (urticaria or palpable purpura).
• Swelling of the abdomen (ascites) – usually a sign of advanced liver disease.
• Bleeding tendency (easily bruising, prolonged bleeding) – indicates impaired clotting factor production.

Because symptoms can be nonspecific, routine screening in at‑risk populations is essential for early detection.

Causes and Risk Factors

How HBV spreads

• Perinatal transmission – Mother‑to‑child during birth (most common route in endemic areas).
• Sexual contact – Unprotected vaginal, anal, or oral sex with an infected partner.
• Blood exposure – Sharing needles, tattoos, or piercings with contaminated equipment.
• Medical exposures – Transfusions, organ transplants, or dialysis with unscreened blood products.
• Household contact – Sharing razors, toothbrushes, or other items that may have blood.

Risk factors for chronic infection

• Age at infection – Over 90% of infants infected < 1 year old become chronic carriers, compared with 5–10% of adults.
• Genetics – Certain HLA types influence immune clearance.
• Co‑infection with HIV, hepatitis C, or hepatitis D increases persistence.
• Immunosuppression – Chemotherapy, organ transplantation, or high‑dose steroids may reactivate dormant HBV.
• Geographic location – Living in or traveling to high‑prevalence regions.

Diagnosis

Diagnosis combines a clinical assessment with laboratory and imaging studies.

Blood tests

• HBsAg (hepatitis B surface antigen) – Presence for >6 months confirms chronic infection.
• HBeAg and anti‑HBe – Indicate viral replication activity.
• HBV DNA quantitative PCR – Measures viral load; guides treatment decisions.
• Liver function panel (ALT, AST, bilirubin, albumin, INR) – Detects inflammation and synthetic function.
• HBsAb (surface antibody) – Determines immunity from vaccination or past infection.

Imaging

• Ultrasound – First‑line to evaluate liver size, texture, and detect focal lesions.
• Transient elastography (FibroScan) – Non‑invasive measurement of liver stiffness, estimating fibrosis stage.
• CT or MRI – Reserved for detailed assessment of cirrhosis or hepatocellular carcinoma (HCC) when ultrasound is inconclusive.

Biopsy (rarely needed)

Liver biopsy provides a definitive fibrosis stage but is replaced in most centers by FibroScan and serum fibrosis markers.

Treatment Options

Therapy aims to suppress viral replication, prevent liver damage, and reduce the risk of cirrhosis or HCC.

Antiviral Medications

• Tenofovir disoproxil fumarate (TDF) – First‑line, high barrier to resistance.
• Tenofovir alafenamide (TAF) – Similar efficacy with lower renal/bone toxicity.
• Entecavir – Another first‑line agent; contraindicated in patients with prior lamivudine resistance.
• Pegylated interferon‑α – Finite‑duration therapy (48 weeks); useful in selected patients who desire a drug‑free endpoint but has more side effects.

Guidelines (AASLD, EASL) recommend lifelong therapy for most patients with high HBV DNA (>2,000 IU/mL) plus elevated ALT or evidence of fibrosis.<sup>[3] AASLD, 2023</sup>

Procedures

• Liver transplantation – Reserved for end‑stage liver disease; HBV can be controlled post‑transplant with antiviral prophylaxis.
• Ablation or resection – For HCC detected early; combined with antiviral therapy to reduce recurrence.

Lifestyle and Supportive Measures

• Avoid alcohol – reduces additive liver injury.
• Maintain a healthy weight; manage diabetes and hyperlipidemia.
• Vaccinate against hepatitis A and, if not already immune, hepatitis D.
• Regular monitoring: ALT, HBV DNA, and fibrosis assessment every 6–12 months.

Living with Chronic Hepatitis B

Daily Management Tips

• Medication adherence – Take antivirals exactly as prescribed; set alarms or use pill boxes.
• Follow‑up appointments – Keep scheduled labs; early detection of flare‑ups improves outcomes.
• Healthy diet – Emphasize fruits, vegetables, whole grains, and lean protein; limit processed foods and added sugars.
• Exercise – Aim for at least 150 minutes of moderate aerobic activity per week.
• Stress management – Chronic inflammation can worsen with stress; consider mindfulness, yoga, or counseling.
• Safe practices – Use condoms, never share needles, and ensure any tattoos or piercings are performed with sterile equipment.
• Inform healthcare providers – Carry a medical alert card or note about HBV status for surgeries or emergency care.

Psychosocial Support

Living with a chronic viral infection can cause anxiety or stigma. Support groups, counseling, and patient education programs (e.g., Hepatitis B Foundation) help improve quality of life.

Prevention

• Vaccination – A three‑dose series (0, 1, 6 months) provides >95% protection. Universal infant vaccination has reduced global prevalence by ~30% since 1990.<sup>[4] WHO, 2022</sup>
• Maternal screening & prophylaxis – Pregnant women should be tested; HBV‑positive mothers receive antiviral therapy in the third trimester and newborns receive hepatitis B immune globulin plus vaccine within 12 hours of birth.
• Safe sex – Consistent condom use reduces transmission risk.
• Harm‑reduction – Needle‑exchange programs and supervised injection facilities lower infection rates among people who inject drugs.
• Infection control in healthcare – Strict adherence to standard precautions and proper sterilization of equipment.

Complications

If untreated, chronic hepatitis B can lead to serious, life‑threatening conditions.

• Fibrosis → Cirrhosis – Scarring impairs liver function; occurs in ~10–20% of chronically infected adults after 20–30 years.<sup>[5] NIH, 2021</sup>
• Hepatocellular carcinoma (HCC) – CHB is one of the leading causes of primary liver cancer worldwide; risk is 15‑20‑fold higher than in the general population.
• Decompensated liver disease – Ascites, variceal bleeding, hepatic encephalopathy, and jaundice.
• Renal complications – Tenofovir can affect kidney function; monitor creatinine regularly.
• Extra‑hepatic manifestations – Polyarteritis nodosa, membranous nephropathy, and certain skin disorders.

When to Seek Emergency Care

References

1. World Health Organization. Global Hepatitis Report 2022. WHO; 2022.
2. Centers for Disease Control and Prevention. Hepatitis B Data and Statistics. CDC; 2023.
3. American Association for the Study of Liver Diseases. 2023 AASLD Guidance on the Treatment of Hepatitis B. Hepatology. 2023.
4. World Health Organization. Hepatitis B Vaccination: WHO Position Paper, 2022. WHO; 2022.
5. National Institutes of Health. Chronic Hepatitis B: Natural History and Management. NIH Liver Disease Research; 2021.

```